PreludeDx – Our Mission

PreludeDx was founded with the goal of providing better decision-making tools to breast cancer patients and physicians. Founded in 2009 with technology licensed from University of California San Francisco, PreludeDx has focused on developing breast cancer tools that will impact a patient’s treatment decision. Our mission is to provide tools that improve patient outcomes in breast cancer and reduce the overall cost burden to the healthcare system.

PreludeDx – Our Values

Patient Focused: We realize that every sample that comes through our laboratory has a patient behind it and it is our job to ensure that we handle each sample with care and provide results back to the patient and physician in a timely manner. PreludeDx exists to take care of the needs of our patients.

Quality First: We will put quality systems and processes first and foremost as we provide the highest quality results to our patients and physicians.

Driving Innovation: PreludeDx will strive to find new innovative tools and processes that assist patients and physicians for the better management of cancer.

Request Info from Our Care Team

Management Team

Daniel Forche
President & CEO

Edwin C. Hendrick
Chief Commercial Officer

Cory Dunn, MS, MEd
Vice President, Global Commercial Marketing

Philip McQuary, Ph.D.
Senior Director, Product Development

David L. Peterson
Vice President, Revenue Cycle

Andrew Sundberg
Vice President, International Sales

Matthew Tate
Vice President, U.S. Sales

David J. Dabbs, MD
Chief of Pathology

Jess Savala, MD
Medical Director

Kristen Apgar
Director, Human Resources and Corporate Administration

Leona Hamrick, DHSc, PA-C, MSL-BC
Senior Director of Global Medical Affairs

Karuna Mittal, PhD
Director, Research and Development

Jasmin Valverde
Director, Operations and Project Management

Board of Directors

Olav Bergheim
Chairman

Daniel Forche
President, CEO, Director

Gerrit Adams
Director

Order Supplies

Customer Care

Licenses & Accreditations